Clinical Trials Logo

Clinical Trial Summary

This was a real-world, prospective, open-label, multicenter study in which participants were randomized (1:1) to receive intravenous (IV) vancomycin or IV daptomycin. The purpose of this study is to compare infection-related hospital length of stay, along with a number of participant-reported outcomes, between participants with complicated skin and soft tissue infection treated with daptomycin and vancomycin.


Clinical Trial Description

Eligible participants will be recruited within 24 hours of hospital admission for cSSSI due to suspected or documented Methicillin-resistant Staphylococcus Aureus (MRSA), and who are anticipated to require IV antibiotics effective against MRSA and at least 3 days of hospitalization for management of cSSSI. The primary objective is to compare infection-related hospital length of stay between participants treated with daptomycin and vancomycin. Secondary objectives were to compare participant reported outcomes (pain symptoms and Health Related Quality of Life), 30 day cSSSI-related hospital readmission rates, and cSSSI-related medical resource utilization and costs between participants treated with daptomycin and vancomycin. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01419184
Study type Interventional
Source Cubist Pharmaceuticals LLC
Contact
Status Completed
Phase Phase 4
Start date September 9, 2011
Completion date October 5, 2012

See also
  Status Clinical Trial Phase
Completed NCT00210899 - Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections Phase 3
Recruiting NCT02566928 - Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence Phase 4
Completed NCT00228982 - Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections Phase 3
Completed NCT01105767 - Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees N/A
Completed NCT01030731 - Pharmacokinetic Study,Ceftobiprole,Healthy Volunteers,Healthy Patients With End Stage Renal Disease Phase 1
Completed NCT00475930 - Chlorhexidine Impregnated Cloths to Prevent Skin and Soft Tissue Infections in Marine Officer Candidates N/A
Completed NCT02814916 - Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA Phase 3
Completed NCT00513799 - The Natural History of Community-Associated MRSA Infections and Decolonization Strategies N/A
Completed NCT00737269 - A Complicated Skin and Soft-tissue Infection Patient Registry Phase 4
Completed NCT00719810 - Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin Infections Phase 2
Terminated NCT00492271 - First Time in Man Trial for Friulimicin B Phase 1
Completed NCT01026740 - Evaluation of Penetration of Ceftobiprole Into Soft Tissue Determined by Microdialysis in Healthy Volunteers Phase 1
Completed NCT00731783 - Staphylococcus Aureus Decolonization Study N/A
Completed NCT01018641 - An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults Phase 1
Terminated NCT00463801 - Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections Phase 4
Completed NCT02582203 - Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA Phase 4
Completed NCT00646958 - Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections Phase 2
Completed NCT00514527 - A Study for Patients With Complicated Skin and Skin Structure Infections Phase 2
Completed NCT01026558 - A Study Evaluating the Pharmacokinetics of Ceftobiprole When Taken by Obese Patients Phase 1
Completed NCT01026636 - A Single-Dose Pharmacokinetics and Safety Study of Ceftobiprole in Pediatric Patients =3 Months to <18 Years of Age Phase 1